Therapeutic platforms for cancer management centered on blocking the PD-L1/PD-1 interaction through the use of aptamers: A review.
A comprehensive analysis of aptamer-driven strategies aimed at inhibiting the PD-1/PD-L1 immune checkpoint pathway is provided, summarizes recent advances in the design of PD-1/PD-L1-targeted aptamer systems and evaluates their potential to enhance therapeutic efficacy while addressing challenges related to immune resistance.